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Grading of meningeal solitary fibrous tumors/hemangiopericytomas (SFTs/HPCs) of the central 
nervous system (CNS) is nowadays based on histologic criteria as described in the revised fourth 
edition of the WHO Classification of CNS tumors [10] or the more recently published, updated 
version of the Marseille Grading System (MGS) [11]. Histology based grading of CNS 
SFTs/HPCs allows for discriminating subgroups with significant differences in prognosis. 
However, the often-piecemeal resection of these tumors may hamper adequate evaluation of 
mitotic activity and necrosis, and thereby assessment of malignancy grade. NAB2–STAT6 fusion 
is the molecular hallmark of both soft tissue SFTs and CNS SFTs/HPCs, and the resulting fusion 
protein accumulates in the nucleus and acts as a transcriptional activator of early growth response 
mediated pathways with STAT6 immunohistochemistry being a very sensitive and specific tool 
for their diagnosis [5, 8, 12, 14]. For soft tissue SFTs, particular NAB2–STAT6 fusion variants as 
well as telomerase reverse transcriptase (TERT) promoter mutations leading to telomerase 
activity and tumor cell immortalization have been reported to have prognostic value. Some 
studies have included CNS SFTs/HPCs in their cohort, but because of small numbers and lack of 
(long term) follow-up data the prognostic value of these markers for CNS SFTs/HPCs is still 
unclear [1–4, 6, 7, 9, 13, 15, 16]. 
 
To evaluate the prognostic value of NAB2–STAT6 fusion variants and TERT promoter mutations 
for CNS SFTs/HPCs, we retrospectively analyzed these markers in a cohort of136 patients with 
STAT6 nucleopositive CNS tumors. All tumors were graded according to the most recent WHO 
classification [10] and the updated MGS [11] and were analyzed for type of NAB2–STAT6 fusion 
and the presence of TERT promoter mutation. For NAB2–STAT6 fusion analysis, we performed 
reverse transcriptase polymerase chain reaction (RT-PCR) after RNA extraction and cDNA 
synthesis using multiple primer sets finding the most common fusion variants which were 
subsequently grouped based on their hypothesized functional effects [3, 15]. 
 
After DNA isolation, amplicons of 163 base pairs spanning TERT promoter hot-spot mutations at 
positions 1,295,228 and 1,295,250 on chromosome 5 were amplified by PCR using the primers 
hTERT-F CAG CGC TGC CTGAAA CTC and hTERT-R GTC CTG CCC CTT CAC CTT and 
subsequent sequencing of the products was performed. More detailed information on Materials 
and Methods is given in the Supplementary Information. For survival analyses, patients who died 
due to complications of initial therapy (e.g., surgery or radiotherapy) were excluded. Results of 
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histological grading, analysis of NAB2–STAT6f usion and TERT promoter mutations and survival 
analysis are listed in Tables 1 and 2. 
 
 
 
Eighty-seven percent of the tumors could be analyzed for NAB2–STAT6 fusion variants using 
RT-PCR (n = 106), in the remaining 30 cases RNA quality was insufficient. Of the 106 tumors, 
26% had an exon4–exon2 fusion (n = 28) and 56% (n = 59) an exon6–exon16/17 fusion. In 18% 
of the tumors (n = 19), no fusion was detected, which may partly be due to our RT-PCR approach 
which did not cover all possible, rarely detected NAB2–STAT6 fusion variants. 
 
In our cohort, the NAB2–STAT6 fusion variants are correlated to both WHO and MGS 
malignancy grade: The exon6–exon16/17 fusion is significantly more frequent in WHO grade II 
and III and MGS grade 2 and 3 tumors(p < 0.0001 and p = 0.006, respectively). 
 
Information regarding extradural metastatic disease was available for 74 cases, and 17 of these 
patients had metastases during their follow-up. In this group of 17 patients, 11(64%) had a tumor 
with exon6–exon16/17 gene fusion and none an exon4–exon2 fusion. In three cases, no fusion 
could be detected with our RT-PCR approach and in three cases, RNA quality was insufficient. 
The results were not statistically significant (p = 0.121), possibly due to the limited number of 
patients with extradural metastatic disease (n = 17). 
 
In addition, a non-significant trend (p = 0.172) towards shorter overall survival was noted for the 
exon6–exon16/17subgroup: of the 19 patients who died from the disease, 12had a tumor with 
exon6–exon16/17 fusion and only 2 withexon4–exon2 fusion. In the remaining five cases, our 
fusion analysis approach did not allow for identification of the exact type of NAB2–STAT6 fusion 
(n = 3) or could not be assessed due to poor RNA quality (n = 2). NAB2–STAT6 gene fusion was 
not correlated to progression-free survival (p = 0.280). TERT promoter mutation status could 
successfully be analyzed in 89% of the tumors (n = 121). Tumors with hot-spot mutations in this 
promoter region were grouped as ‘TERTp-mutant’ and those without such mutations as ‘TERTp-
wildtype’. In 68% of the cases, the tumor was found to be TERTp-wildtype (n = 82), and in 32% 
TERTp-mutant (n = 39). TERT promoter mutation was not significantly correlated with NAB2–
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STAT6 fusion type (p = 0.164), WHO grade (p = 0.854) or MGS grade (p = 0.519). In addition, 
TERT promoter mutation was not significantly correlated with metastatic disease (p = 0.090), 
progression-free survival(p = 0.635) or overall survival (p = 0.107), albeit a trend was noted for 
less aggressive clinical course in TERTp-mutant tumors, which is contradictory to published 
results in soft tissue SFT [2, 7]. Survival curves for NAB2–STAT6 fusion groups and the presence 
of TERT promoter mutation are provided in the Supplementary Information. 
 
In summary, although in our relatively large cohort of CNS SFTs/HPCs the type of NAB2–STAT6 
fusion lacks significant prognostic value, tumors with an exon6–exon16/17 fusion do show a 
tendency towards more malignant behavior compared to tumors with exon4–exon2 fusion. This 
difference in aggressiveness may be explained by the presence of different functional domains 
within the chimeric NAB2–STAT6 protein in different fusion groups, with, e.g., the CID domain 
of NAB2 only integrated in the exon4–exon2 variant resulting in EGR1 activation and fibrosis as 
seen in the low-grade groups as hypothesized by Barthelmeβ et al. [3]. Furthermore, in contrast to 
studies on mainly extradural SFTs in which TERT promoter mutation was shown to indicate poor 
disease-free survival, in our cohort clear prognostic value of TERT promoter mutation status was 
lacking. Based on our study we conclude that so far, histology-based grading incorporating 
mitotic activity and necrosis remains the best indicator of prognosis in SFTs/HPCs of the CNS. 
However, given the trend towards more malignant behavior in the exon6–exon16/17 fusion group 
future and larger studies are needed to sort out if esp. NAB2–STAT6 fusion analysis may be of 
additional value in histology-based prognostic models after all.  
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Supplementary Information Text 
Materials and Methods 
Patient cohort and sample selection 
Patients with a diagnosis of meningeal SFT or HPC were retrospectively selected from the (referral) files 
of the authors. For each case, one representative tumor tissue block of the resection specimen was 
retrieved from the pathology archives of the participating hospitals and included for histomorphological 
assessment and gene fusion analysis. 
Clinical data including age at first histological diagnosis and follow-up data were extracted from the patient 
files. Extradural metastatic disease was detected by imaging techniques (with no other malignancies 
known) and/or proven by histological assessment. Progression-free survival is counted in months from 
date of first histological diagnosis to date of diagnosis of the (first) local recurrence, growth of residual 
disease for which therapy was required or detection of metastasis. Overall survival is counted in months 
from date of first histological diagnosis to date of last known follow-up or date of death. Distinction was 
made between patients who died due to disease-related factors (i.e. disease-specific survival; DSS) and 
patients who died due to other causes.    
This study was approved by the local scientific review board and was performed in accordance with the 
Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands. The French Samples 
used in this study were stored and retrieved from the APHM Tumor Bank (authorization number: AC2018-
31053; CRB BB-0033-00097), which respects the ethical charter of the French National Cancer Institute to 
store and deliver samples for scientific research according to the French Public Health Code (articles L. 
1243-4 and R. 1243-61). All samples were obtained after informed consent from patients or their parents 
when the patients were under the age of 18. As this research was not interventional, it did not require an 
approval by an ethics committee. The French committee for the treatment of biomedical research 
information approved the data management of this study (C.C.T.I.R.S. - 09.084Ter). 
Assessment of histomorphological features 
Four µm thick sections were stained with hematoxylin and eosin and all cases were reviewed by three of 
the authors (UF, BK, RV). Diagnosis and WHO grade were assigned according to the 2016 WHO 
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Classification of Tumours of the Central Nervous System [WHO]. The updated Marseille Grading System 
[Macagno 2018] was applied on all cases by two authors (NM, CB). 
All cases were confirmed by STAT6 nuclear staining of tumor cells using an already published protocol [1]. 
NAB2-STAT6 gene fusion analysis and TERT promoter mutation analysis 
NAB2-STAT6 gene fusion analysis and TERT promoter mutation analysis was performed on all cases. 
Briefly, RNA was extracted from formalin-fixed, paraffin-embedded tissue using RNA-Bee-RNA isolation 
reagent (Bio-Connect BV, Huissen, the Netherlands). RNA quantity and quality were determined by a 
NanoDrop measurement (Fisher Scientific, Landsmeer, the Netherlands) and subsequently, cDNA 
synthesis was performed using Superscript II (Invitrogen Life Technologies Europe, Bleiswijk, the 
Netherlands) and random hexamers (Promega Nederland, Leiden, the Netherlands). The cDNA was 
tested by the reverse transcription-polymerase chain reaction (RT-PCR) for the HMBS 
(hydroxymethylbilase synthase) housekeeping gene using the primers forw150 5’-
TGCCAGAGAAGAGTGTGGTG-3’ and rev150 5’-ATGATGGCACTGAACTCCTG-3’. Samples without 
cDNA template were amplified in parallel as negative controls. 
For the detection of the most common NAB2-STAT6 gene fusions, three primers in NAB2 (NM_005967.3): 
forw 5’- CAAGTAGCCCGAGAGAGCAC-3’ (exon 3), forw 5’- CTCCACTGAAGAAGCTGAAAC-3’ (exon 4) 
and forw 5’-CTGTGTGCCTGCGAAGCC-3’ (exon 6) were used in combination with three primers in 
STAT6 (NM_001178078.1): rev 5’-GGGAAAGTCGACATAGAGCC-3’ (exon 2), rev 5’-
GAGCTGAGCAAGATCCCGG-3’ (exon 16) and rev 5’-TTCCACGGTCATCTTGATGG-3’ (exon 17). The 
PCR products were analyzed by agarose gel electrophoresis. 
PCR was applied to amplify the TERT promoter region using the following primers: hTERT-F: 
CAGCGCTGCCTGAAACTC and hTERT-R GTCCTGCCCCTTCACCTT, amplifying a 163-bp fragment 
spanning hot-spot mutations at positions 1,295,228 and 1,295,250 on chromosome 5. Sequencing was 
done on an Illumina MiSeq next generation sequencer. Adapter ligation and barcoding was done using the 
NEBNext Ultra DNA Library Prep Mastermix Set and NEBNext Multiplex Oligos from New England 
Biolabs. CLC Cancer Research Workbench software from QIAGEN® was performed for sequence 
analysis. Described briefly, the analysis workflow included adapter trimming and read pair merging before 
mapping to the human reference genome (hg19). Insertions and deletions as well as single nucleotide 
variants were detected. Additional information regarding potential mutation type, known single nucleotide 
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polymorphisms and conservation scores was obtained by cross-referencing various databases (COSMIC, 
ClinVar, dbSNP, 1000 Genomes Project, HAPMAP and PhastCons-Conservation_scores_hg19). 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics v22.0. 
Comparison of different NAB2-STAT6 fusion variants with various clinical and histomorphological 
parameters were evaluated by using the χ2- or Fisher’s exact test as appropriate. 
Progression-free- and disease-specific overall survival were used as end points as defined above. Kaplan-
Meier curves were plotted for visualizing survival in different NAB2-STAT6 fusion variant groups and the 
log-rank test was used for comparing the difference between the groups. For survival analysis, patients 
who died due to complications of initial therapy (e.g. surgery or radiotherapy) were excluded. 
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Supplementary Information Figures 
Figure 1a: Overall survival in different NAB2-STAT6 fusion groups of 
solitary fibrous tumors/hemangiopericytomas of the central nervous 
system 
 
Log-rank p = 0.172 
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Figure 1b: Overall survival in TERT promoter-mutant versus TERT 
promoter-wildtype solitary fibrous tumors/hemangiopericytomas of the 
central nervous system 
 
Log-rank p = 0.107 
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Figure 2a: Progression-free survival in different NAB2-STAT6 fusion 
groups of solitary fibrous tumors/hemangiopericytomas of the central 
nervous system 
 
 
Log-rank p = 0.280 
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Figure 2b: Progression-free survival in TERT promoter-mutant versus 
TERT promoter-wildtype solitary fibrous tumors/hemangiopericytomas 
of the central nervous system 
 
Log-rank p = 0.635 
 
